<?xml version="1.0" encoding="UTF-8"?>
<p id="p0340">A different investigation compared patients treated with FPV plus interferon inhalation to LPV/RTV. Patients under FPV therapy responded better to the progression of the disease with accentuated viral depuration. Also, the incidence of nausea and vomit was higher for LPV/RTV.
 <xref rid="b0825" ref-type="bibr">
  <sup>165</sup>
 </xref> In addition to these clinical trials, the antiviral activity of FPV against SARS-CoV-2 was also evaluated but no clear antiviral effect was noted for doses lower than 100 μM.
 <xref rid="b0545" ref-type="bibr">
  <sup>109</sup>
 </xref> Albeit its relative safety and efficacy, information obtained thus far are inconclusive regarding FPV for anti-SARS-CoV2 activity. Signs of clinical improvement of patients reinforce the need for monitoring outcomes of current clinical trials as they can elucidate the role of FPV in the fight against COVID-19.
 <xref rid="b0830" ref-type="bibr">
  <sup>166</sup>
 </xref>
</p>
